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Medullary thyroid carcinoma is of interest because a proportion of cases are familial. The tumour arises from the thyroid 'C' cells, which secrete calcitonin. It is inherited in autosomal dominant fashion with high penetrance. It is therefore possible to screen family members at risk by assays of plasma calcitonin, in the hope of diagnosing the tumour at a stage when it is curable by thyroidectomy. This review will discuss the methods of screening, the evidence of benefit, and the potential problems. Even in an apparently straightforward situation such as this, the best policy for screening families is not clear.
Types of medullary thyroid carcinoma (MTC) MTC occurs in a sporadic and in a familial form (Table 1) . It is generally estimated that about 80% of patients with MTC have the sporadic form (Chong et al. 1975 ), but the proportion of familial cases may have been underestimated. Apparently sporadic cases Estimates of the proportion of sporadic cases are based on the criterion of a negative family history. A negative family history may, however, be misleading even if carefully taken, either because the disease has not been detected in an affected parent (e.g. 11-3 in Figure 1 ) or because the patient is in fact a new mutation to the familial form (e.g. Figure 2 ). In the latter case, of course, only the children of the patient will be at risk.
It is probably wise to regard any patient who is not obviously of the familial type as 'apparently' sporadic until screening of the appropriate relatives is known to be negative. An estimate of the probability that any given apparently sporadic case is in fact familial is a major factor in the decision to initiate screening. This problem will be discussed in detail below. family. The index case is arrowed. Note that 11-3 died (aged 66, of 'bronchitis') apparently unaffected, but had an affected daughter (III-6) of serum calcium: the frequency of parathyroid abnormality ranges in different series from zero to around 50% (Melvin et al. 1972 , Williams 1979 , probably depending on the energy with which it has been sought. MEN 2b, distinguished by the phenotype of neuromas of the buccal cavity, lips and eyelids, ganglioneuromatosis of the bowel and Marfanoid features (Gorlin et al. 1968 , Dyck et al. 1979 , Carney & Hayles 1977 , Riley & Robertson 1981 , is uncommon. much younger age than in MEN 2a, and the tumour is usually aggressive (Norton et al. 1979 ). Evidence of familial involvement is lacking in many MEN 2b cases, but it is not clear whether these are genuinely sporadic, or new mutations who have not had children who can be assessed for inheritance.
Inheritance
Familial MTC is inherited in an autosomal dominant pattern ( Figure 1 ). The penetrance of the syndrome is high: literature reports and our own preliminary data (CRC Medullary Thyroid Group, unpublished) suggest that over 90% of individuals who inherit the gene will present clinically with thyroid tumours by the age of 60 years (Figure 3) . A few of the remainder may prove to have a thyroid abnormality on clinical examination although they have not sought advice, and it is probable that the remainder will have an abnormal basal or provoked calcitonin level, even though clinically normal. That carriers of the gene may sometimes be missed on family historyfor example 11-3 in Figure 1 must be borne in mind both when deciding to eliminate a branch of a family from screening, and when deciding whether a new case is truly of the sporadic variety.
Development of MTC in familial cases
Familial MTC and the associated phaeochromocytomas develop from multiple foci of hyperplasia of the thyroid C-cells or the adrenal medulla (Block et al. 1980 , Cerny et al. 1982 , Webb et al. 1980 . It is a useful concept, though possibly an over-simplification, to regard the C-cell hyperplasia in familial cases as a direct expression of the inherited mutation which is expressed in every C-cell in individuals with the familial variety (Jackson et al. 1979) . In sporadic cases, by contrast, affected C-cells would have to acquire the same change by somatic mutation, which is a rare event. Multiple areas of C-cell hyperplasia would therefore not be expected.
The development of familial MTC through a stage of C-cell hyperplasia has two consequences for screening. First, it provides a time when an increased C-cell mass can be detected by calcitonin measurement, before the development of invasive tumours. Second, if C-cell hyperplasia is truly pathognomonic of the inherited tumour, review of the pathology of thyroids resected for MTC may allow the recognition of the familial index cases from among the mass of apparently sporadic ones. The evidence that C-cell hyperplasia is a reliable indicator of the familial syndrome is strong (Jackson et al. 1979 , Emmertsen et al. 1983 . It is, however, still incomplete because the circumstances in which it will be potentially most valuablethe recognition of the familial syndrome in the apparently sporadic index caseare precisely those where its accuracy is difficult to validate. Family screening over many years will be required to show how many of the apparently sporadic cases with C-cell hyperplasia are in fact familial.
Screening procedures
Screening for MEN 2 syndrome has three components: history, physical examination'and investigation.
The taking of a good family history is vital, but usually in hospital practice it is badly done. The pedigree does not need to be very extensive, although the chances of missing (say) an affected parent who died young of some other cause, or in whom the disease was not clinically evident, can be'lessened by enquiry about uncles and aunts and cousins, as well as first-degree relatives. Accuracy is likely to be greatly improved if the patient is first asked to name each of the relatives, and is then asked specifically about each one, including leading questions relevant to the syndrome (e.g. neck swelling, early death from cardiovascular disease). It is surprising how many forgotten siblings, aunts and uncles that systematic naming of the relatives can produce. Naming individuals brings them into focus and improves recollection of their illnesses. The potential for improvement is illustrated by the 9 families known to the CRC Medullary Thyroid Group in which the diagnosis was made because the disease presented clinically in more than one family member (unpublished data). In 5 of the 9, a third or even a fourth member had been diagnosed before the familial involvement was recognized. The delay in diagnosis in these and the other family members at risk may well have prejudiced their treatment.
Physical examination includes a search for signs of the thyroid tumour and of phaeochromocytoma, and a search for the physical abnormalities suggestive of the MEN 2b phenotype described above.
Screening investigations for the thyroid tumour are all based on measurement of plasma calcitonin. Ultrasound, CT or radionuclide imaging are unlikely to yield useful information at this stage. Most family screening is based on the use of stimulation tests. By the time the C-cell mass has increased sufficiently to cause an elevation in basal (unstimulated) plasma calcitonin, some patients will have developed invasive medullary thyroid cancer (Wells et al. 1978a (Wells et al. , 1982 . Some will have evidence of lymph node metastasis at operation, and despite apparently complete surgical resection, some will have a persistently raised calcitonin postoperatively, which is suggestive of residual disease outside the thyroid. Individuals picked up by abnormalities of stimulated calcitonin levels, at a time when basal calcitonin is still normal, are less likely to have lymph node involvement or abnormal postoperative calcitonin levels (Wells et al. 1978a (Wells et al. , 1982 .
Current practice is to begin screening in known families at the age of 5 or 6 years, and to continue at intervals of a year or so until age 40 (Gagel et al. 1982) , perhaps increasing the interval between tests after the age of 20.
Screening tests, whether basal or stimulated, are usually performed in the morning after a light breakfast, because of the possible effects of food in stimulating calcitonin secretion, although this is probably an unnecessary refinement. Alcohol, pentagastrin and calcium have been used as provocative stimuli (Dymling et al. 1976 , Telenius-Berg et al. 1977 , Wells et al. 1978b , Emmertsen et al. 1980 , Verdy et al. 1978 . The merits of each are still debated (Baylin & Wells 1981) . Alcohol (50 ml whisky by mouth) has been claimed to be the most acceptable (Dymling et al. 1976) (though perhaps risky if the subject is going to drive), but it may be less reliable, giving an unacceptable number of false-negative results (Emmertsen et al. 1980 ). Pentagastrin (0.5 jug/kg i.v. in 2-5 ml normal saline in 10 seconds) or calcium gluconate (2 mg Ca+ +/kg/l minute) may be more reliable, but the side effects have been held to be less acceptable. Pentagastrin causes in most subjects a variable combination of an unpleasant feeling of warmth in the throat, gastric discomfort and abdominal cramps, tightness in the chest, nausea and tingling in the limbs. Rarely a subject has fainted: it is probably best, therefore, to do the test with the subject lying rather than sitting. Although they sound alarming, the effects invariably subside completely within two minutes; and in the author's experience of repeated tests in over forty individuals, suitably warned of what to expect, none has suffered serious distress or refused a second test. Calcium infusion is also associated with unpleasant sensations of warmth, tingling and nausea. It has been claimed that a combined calcium-pentagastrin test offers maximum reliability, with no increase in discomfort (Wells et al. 1978a ). Most groups with a substantial involvement in family screening now use the pentagastrin or calcium stimuli.
Many authors have discussed the interpretation of the results (Ba-ylin & Wells 1981 , Heath & Sizemore 1982 . Although 'MTC is among the least common causes of a raised calcitonin' (Becker et al. 1982) , most of the conditions likely to give a misleading result, which include other neoplasms, chronic renal failure, pregnancy, and oral contraceptives, should be easily discovered if they arc sought when an unexpected result is obtained. Note that normal values may be up to 3-fold higher in children (Samaan et al. 1975 , Deftos et al. 1980 , and the normal ranges quoted for many assays are based on adults only. Another pitfall is the presence in the plasma of some otherwise normal individuals of substances which cross-react with calcitonin in the assay, to give spurious elevated results. The extent of this problem appears to vary between laboratories, depending upon the methods and the antibody used. Interference of this kind probably only gives false-positive results up to about 6 times the upper limit of normal, but this is the range likely to be encountered in screening normal family members. 'Borderline' elevations of basal calcitonin (up to IO' normal) which are due to MTC may perhaps be distinguished from those which are not by a stimulation test: the peak response to pentagastrin should be at least twice the resting value before the result is accepted as due to MTC.
Familiarity with the characteristics and normal ranges of the particular assay which has been used are very important. Those responsible for the assay invariably welcome contact from the clinician to discuss such problems.
Any positive result should be confirmed by a second test, possibly more, before deciding on surgery. Individuals with equivocal results should (according to the clinical context) be observed with repeat tests at intervals of months or a year. The criteria for recommending surgery are discussed in more detail below, but will depend on the behaviour of the tumour in other family members, the attitude of the family, the attitude of the surgeon, and previous experience with the calcitonin assay in relation to calcitonin values of the same level. Although a rising trend of calcitonin values may be sought as evidence of progressive tumour development, it should not necessarily be expected. Many investigators have reported fluctuation in levels between successive tests, even a normal result between two clearly abnormal ones (Graze et al. 1978) , presumably because of day-to-day variation in the calcitonin stores in the C-cells.
Screening for associated phaeochromocytomas may be attempted by blood pressure measurement, assay of urinary or plasma catecholamines, or by imaging. (Although regular screening for phaeochromocytomas is certainly warranted in known families, the yield in relatives of apparently sporadic cases of MTC seems likely to be low.) The best approach will depend upon local facilities and expertise. Urinary catecholamines may be normal in the presence of significant tumour, and interpretation of plasma catecholamines may be difficult for the inexperienced (Brown et al. 1981) . Probably the most satisfactory screen both logistically and diagnostically is adrenal imaging, by ultrasound or preferably by CT scan (Stewart et al. 1978) . It is not clear whether 13"I meta-iodo-benzylguanidine adrenal imaging , Sisson et al. 1981 ) is yet sufficiently accurate for screening, as opposed to the diagnosis of metastatic disease.
Parathyroid involvement is usually subclinical. A serum calcium should be checked at the initial screening. Individuals with suspected or proven MTC should also be screened for hypercalcaemia and associated pathology, in particular renal calculi. Measurement of parathormone is probably not justified as a routine screening investigation.
Is screening of benefit?
There is still no direct evidence that a policy of systematic family screening for MTC is of benefit, although the circumstantial evidence is strong. The risks of undiagnosed phaeochromocytoma, especially during anaesthesia and childbirth (Fletcher 1978) , suggest that screening family members for this tumour is at least prudent.
Circumstantial evidence that early diagnosis of MTC by screening is beneficial is threefold. (1) There is no doubt that people die of the familial MTC syndrome. Ten-year survival in many series (containing both familial and sporadic cases) is about 60% (Rougier et al. 1983) , and most of the deaths are attributable to the syndrome. There seems no evidence that, overall, the familial variety of MTC is less likely to kill than the sporadic variety, despite an impression to the contrary which seems to be based on published accounts of some families in which the disease runs an unusually benign course. (2) The great majority of patients who die of the disease have evidence of extrathyroidal disease at the time of first operation. Moreover, in one series, histological evidence of lymph node involvement was found in 15 of 24 patients picked up with clinically evident disease at screening, but in only 2 of 22 patients whose only abnormality was a raised stimulated calcitonin (Wells et al. 1978a) . A second paper from the same group showed that the extent of disease was correlated with the absolute level of the peak calcitonin response following stimulation (Wells et al. 1982) . On the face of it, therefore, the earlier the diagnosis is made, the better.
(3) In centres where screening programmes were initiated several years ago, whereas the first round of screening yielded many family members with advanced disease, regular follow-up screening revealed individuals at the stage of C-cell hyperplasia or microscopic tumour (Graze et al. 1978) . Only prolonged follow up will prove that these screened individuals are in fact at very low risk of metastatic disease: it could be argued that there is a minority of individuals who have aggressive disease in whom the disease spreads early, and that screening, even at the earliest stage, may not be of benefit. The weight of the evidence, however, seems otherwise.
Costs of screening
The potential benefits of screening must be considered in relation to the costs. Some people argue against screening families at all because of the anxiety and uncertainty which may be engendered. For example, affected individuals may be made to feel guilt at having passed a 'defect' to their children. Screening of children undertaken annually from the age of 6 to 35 or so is both a considerable logistical undertaking as well as a burden of anxiety on the parents. Quite commonly, 'borderline' elevations of calcitonin will be found. Individuals will ask for the result and know that it is equivocal and that screening must be repeated, perhaps at a shorter interval. This uncertainty can be difficult to accept. Finally, the treatment itself has morbidity: thyroidectomy carries a risk of laryngeal nerve damage and of hypoparathyroidism which will vary with the expertise of the surgeon. Although the risk is usually 1% or less, these are significant complications for the individual who suffers them.
The psychological morbidity of screening can probably be greatly reduced if the family can deal consistently with one doctor or with members of a small team, who are readily available and who clearly have time to discuss their anxieties with them. At the Royal Marsden Hospital, we have developed an approach to screening which is shown in Figure 4 . We have been particularly cautious because screening is being offered to relatives of patients without an evident family history (for reasons discussed below), whose families have therefore no idea that the possibility of a familial cancer exists. The index patient is seen in the hospital; screening is explained and, if the patient agrees, a social worker specifically trained in genetic problems arranges to visit him at home to explain the screening again on his own ground, and to obtain a more detailed family history using family photographs, etc. Permission is obtained from the index case to approach the first-degree relatives; but before physician is involved throughout they are contacted the physician in charge of the screening also asks the advice and permission of the general practitioner of each one (identified, if necessary, from NHS central records). Our social worker visits each of the relatives at home, and only then, if they want to be screened, does the physician contact them personally by letter or telephone to arrange an appointment. With this approach, 2 out of 18 families in whom there was no prior evidence of familial involvement have declined screening. We think that no family has been upset by the initial contact (although in one family anxiety was subsequently provoked in one member because of a series of markedly inconsistent calcitonin results which remains unexplained).
Who should be screened?
As with other decisions in medicine, the decision to screen rests ultimately on a judgment of likely benefits versus likely costs, and this will vary from family to family. There are two distinct clinical problems: the family of the apparently sporadic index case, and the members of a known MEN 2 family.
Families of apparently sporadic cases Consider the 'apparently sporadic' case illustrated in Figure 2 . There is no evident family history, although the parents (who would have been the most informative relatives) are dead. Should the brothers (111-1 and 2) be screened? Three questions arise: (1) if a positive result were obtained, would the probability that it was a genuine result, due to MTC, be greater than that it was a false-positive? (2) Would a genuine positive be 'worth' discovering anyway? (in terms of the benefit to individuals who are already 50 years old with no clinically detectable tumour, perhaps not; but the implications for the children must not be forgotten).
(3) If the screening result is negative, need it be repeated? -in other words, is the penetrance of the gene such that it is always detectable by stimulation tests at this age? (The answer is probably (Gagel et al. 1982 ) that, if present, the effect of the gene will be detectable at this age, so the test need not be repeated.) There is a fourth, more general, question: will the overall likelihood of benefit to the family, who are probably unaware that there is any question of an inherited cancer, outweigh the possible costs? With the children of the index case there are similar problems. Their risk is in theory greater, because their father might be a new mutation to the inherited syndrome, and because they are young and so less likely to have manifested the gene clinically than their 50-year-old uncles. On the other hand, the decision to screen implies a commitment over twenty or more years. At present, these decisions must be based on clinical judgment with little factual support. Age-at-onset data suggest that the majority of familial cases have presented clinically by the age of 45. One might therefore estimate the risk of familial involvement to be less if the index case presented over, say the age of 50, and less still if there are a large number of healthy, elderly, first-degree relatives; but how much less, and whether it is too small to bother about, one cannot say. Furthermore, we do not know the incidence of new mutations, which is required to estimate the prior genetic risk to the children of apparently sporadic cases. Risk estimates would be greatly improved if the truly familial index case could reliably be distinguished from the truly sporadic. The use of C-cell hyperplasia to make this distinction was mentioned earlier and will be discussed again in the final section.
Relatives in known families
The second clinical setting in which screening decisions must be made is the already recognized family. Here, first-degree relatives of affected members are known to have a prior genetic risk of 50%, and so the justification for screening seems clear.
The first problem is that as the generations pass, the family expands, and the screening of large numbers of children from early childhood until middle age becomes a major problem. In theory, one should be able to eliminate some branches of the family because a parent or grandparent was unaffected, but the pedigree in Figure 1 shows that this cannot reliably be done on clinical grounds: for example, II-3 died apparently unaffected aged 66, and had an affected daughter. To exclude branches of the family from screening, it will be necessary to know at what age an individual can confidently be assigned as not carrying the gene on the basis of any particular test. Ultimately, linkage studies (see final section) may provide a genetic marker of the inherited gene which, if sufficiently tightly linked, will allow one to identify in childhood all the individuals who are not at risk, and eliminate them from screening.
A second, different, problem is that in some families the thyroid tumours seem to be indolent, and compatible with a normal lifespan without serious morbidity. Because of this, it has been questioned whether early thyroidectomy is justifiable; and it follows that if there is no intention to act upon an early diagnosis, screening becomes an unnecessary interference. The danger of this argument is that while the tumour has shown consistent behaviour in some families, in others it has been variable (Stevenson et al. 1981 , Emmertsen et al. 1982 , and a relaxed approach to screening in some such families has resulted in late diagnosis of individuals with aggressive disease who might possibly have been successfully treated at an earlier stage. Until it has been proved that screening is truly of benefit (see earlier), the argument about the best approach to family screening cannot be resolved: but the majority opinion at present is in favour of regular stimulated calcitonin testing and thyroidectomy on the basis of these results, without waiting for clinical evidence of thyroid tumour.
Future prospects
Antibodies are now available to the calcitonin N-terminal flanking peptide, which has been called PDN-21 or katacalcin (Hillyard et al. 1983) . Calcitonin and katacalcin are translated from a common mRNA precursor and secreted in parallel both in normal and MTC tissue (Hillyard et al. 1983 , Roos et al. 1983 ). Radioimmunoassay for katacalcin may possibly provide a cross-check of borderline immunoreactive calcitonin values, and allow discrimination of those which are due to nonspecific immunological cross-reactions with the calcitonin antibody. Similar discrimination, at the cost of a more time-consuming assay procedure, may be provided by assays in which calcitonin is first extracted from plasma before radioimmunoassay (Heath & Sizemore 1982 , Body & Heath 1983 .
The common clinical problem of whether to screen the families of apparently sporadic index cases may be resolved if multifocal C-cell hyperplasia can be validated as an accurate discriminator of the familial from the sporadic case (Jackson et al. 1979 , Emmertsen et al. 1983 , Wolfe & DeLellis 1981 . Retrospective review of resected thyroid tissue is generally unsatisfactory, because one cannot be sure that the tissue blocks will include the appropriate region of the normal thyroid where the C-cells are found. The diagnosis of MTC is generally not suspected in apparently sporadic cases until after thyroidectomy. If C-cell hyperplasia is to be useful in this context, it will be necessary to persuade all surgeons and pathologists to set aside at the time of the operation an appropriate slice of thyroid tissue from all resections for tumour, for subsequent review if the diagnosis should prove to be MTC.
Finally, the prospects have greatly improved for genetic linkage studies in families to identify genetic markers which segregate with the tumour. Common sites of DNA sequence polymorphism in the population are rapidly being identified by the use of 'restriction enzymes', which cleave DNA at specific nucleotide sequences. The polymorphic sequences are being mapped on the chromosomes, and will provide an almost limitless set of genetic markers to replace the few 'classical markers', such as blood group and HLA polymorphism, which were previously available (Bishop & Skolnick 1980) . The application of these markers in detection of carriers of the genes for sickle cell anaemia (Kan & Dozy 1978) , Duchenne muscular dystrophy (Murray et al. 1982 ) and Huntingdon's chorea (Gusella et al. 1983 ) has already been reported. In the next few years, a similar analysis should be possible for familial MTC syndromes. This will have clinical application in the identification of individuals at risk. If it leads to the identification of the genetic defect in these syndromes, it will be of fundamental biological interest as well.
